GlassScriptPhysician profile
Azhar Aslam
NPI 1457380156
$11,078.82
in general payments reported to CMS, 2019-2025
51 companies · $1,107 in 2025
The $1,107 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,159 · 2020: $1,879 · 2021: $742 · 2022: $830 · 2023: $2,977 · 2024: $1,385 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,610 · Travel and Lodging: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,610.31 |
| Travel and Lodging | $858.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,695.69 | 2019-2025 | Optis, Cardiomems, Navitor |
| Boston Scientific Corporation | $1,353.73 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd, Bodyguardian |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,285.33 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $814.93 | 2019-2023 | Xarelto |
| Aop Health US, LLC | $767.00 | 2025 | Rapiblyk |
| Amgen INC. | $759.70 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $635.66 | 2019-2024 | Brilinta, Farxiga, Andexxa |
| Edwards Lifesciences Corporation | $297.05 | 2019-2025 | Sapien 3 Ultra Resilia |
| Inari Medical, INC. | $222.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $222.63 | 2019-2025 | |
| Abbvie INC. | $210.57 | 2023 | Dalvance |
| Sanofi-Aventis U.S. LLC | $202.73 | 2019-2022 | |
| Novo Nordisk INC | $201.58 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $178.92 | 2022-2025 | |
| Amarin Pharma, INC. | $174.58 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azhar Aslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.